Haloperidol and Risperidone efficacy for Attention Deficit Hyperactivity Disorder treatment
Not Applicable
- Conditions
- Attention deficit hyperactivity disorder.hyperkinetic disorder
- Registration Number
- IRCT2015082623766N1
- Lead Sponsor
- vice chancellor for research of Ahwaz Jondishapour University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 46
Inclusion Criteria
inclusion criteria: three to six years old children with attention deficit hyperactivity disorder; parent consent; ADHD rating scale greater than 20 and C-GAS lower than 50.
exclusion criteria:any other medical or psychiatric comorbidity like mood disorder; anxiety disorder; mental retardation; psychotic disorder; tic; pervasive developemental disorder and taking any pharmacological or non pharmacological treatment in two weeks prior to study.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Attention deficit hyperactivity disorder score. Timepoint: baseline and 2 weeks, 4weeks, 6weeks after intervention. Method of measurement: Attention deficit hyperactivity disorder rating scale questionarie.;Children's Global Assessment. Timepoint: baseline and 6 weeks after intervention. Method of measurement: Children's Global Assessment Scale questionarie.;Attention deficit hyperactivity disorder score. Timepoint: baseline and 2 weeks, 4weeks, 6 weeks after intervention. Method of measurement: Conners Rating Scale-Parent version questionarie.
- Secondary Outcome Measures
Name Time Method Drug side effects. Timepoint: 2 weeks, 4weeks, 6weeks after intervention. Method of measurement: Side effect questionaire.